Molecular genetic diagnostics is required for all patients with persistently raised Phe, as treatments and outcome vary, depending on the underlying defect, including PAH, BH4, or more recently the co-chaperone DNAJC12 defects [18]. Here, DNAJC12 is linked to pulmonary arterial hypertension.